Ha - Study guides, Class notes & Summaries

ATI Pharmacology Proctor 2019 SET 1 COMPLETE GUIDE WITH QUESTIONS AND ANSWERS A+ GRADED A nurse is assessing a client who is receiving intravenous therapy. The nurse should identify which of the following findings as a manifestation of fluid volume excess? a. Decreased bowel sounds b. Distended neck veins c. Bilateral muscle weakness d. Thread pulse - ANS b. Distended neck veins A nurse is caring for a client who has hyponatremia and is receiving an infusion of a prescribed hyperto...

MN 553 UNIT 1 QUIZ | MN 553: ADVANCED PHARMACOLOGY & PHARMACOTHERAPEUTICS | COMPLETE TEST BANK | CHAPTERS 1-52 WITH CORRECT ANSWERS. Drugs administered via IV: 1 . Need to be lipid soluble in order to be easily absorbed 2 Begin distribution into the body immediately . 3 . Are easily absorbed if they are nonionized 4 . May use pinocytosis to be absorbed 14. When a medication is added to a regimen for a synergistic effect, the combined effect of the drugs is: 1 . The sum of the effe...

1. Which patient population is more sensitive to dosage errors? A. Male patients ages 25-40 B. Bariatric patients C. A patient with a history of polypharmacy D. Pediatric patients - D. Pediatric patients Rationale: Pediatric patients are at higher risk of medication errors related to dosing for body size. Patient weight should always be recorded in kilograms for medication dosage calculations. Other populations at high risk including geriatric patients and those patient with impaired body system...

MN 553 Pharm Final Questions With Complete Solutions

ATI Pharmacology Proctor 2019 SET 1 Questions and Answers Rated A+ Latest 2023

MN 553 Advanced Pharmacology Unit 9 Quiz | Questions with Correct Answers 2023/2024 | Latest Update. A genetic variation in how the metabolite of the cancer drug irinotecan SN-38 is inactivated by the body may lead to: Question options: Decreased effectiveness of irinotecan in the treatment of cancer Increased adverse drug reactions, such as neutropenia Delayed metabolism of the prodrug irinotecan into the active metabolite SN-38 Increased concerns for irinotecan being carcinogenic Questi...